

PRE-EXPOSURE PROPHYLAXIS IN SERO-DISCORDANT MALE PARTNERS OF HIV POSITIVE WOMEN DESIROUS OF NATURAL CONCEPTION

ADETUNJI OLADENI ADENJI, ADEWALE SAMSON ADEYEMI & KOLA MUSLIUDIN OWONIKOKO

Department of Obstetrics & Gynaecology, Faculty of Clinical Sciences, College of Health Sciences, Ladoké Akintola University of Technology, Ogbomosho, Oyo State, Nigeria

ABSTRACT

Background

The reproductive health needs of sero-discordant couples are issues of concerns, especially in view of high cost of various assisted conception methods in the low-resource economies. Often times, many of these couples resort to un-informed and unsafe practices of unprotected heterosexual intercourse, leading to HIV acquisition. The magnitude of the health burden of these populations in Nigeria and other developing economies are currently not fully determined. Pre-exposure prophylaxis (PrEP) in conjunction with other HIV prevention strategies provides the only veritable and possibly safe mean of achieving their reproductive desire.

Materials & Methods

This is a cohort study of 42 HIV-1 sero-discordant male partners of known HIV-1 positive women who were desirous of conception. All the male Participants recruited were aware of their female partners' status, had their HIV status determined by fourth generation Enzyme Linked Immunosorbent Assay Kit and were HIV negative, but declined the offer of assisted conception. The HIV positive women were all on Highly Active Antiretroviral Therapy (HAART). Thirty sero-discordant partners were sequentially and equally randomised into the two treatment groups (TDF and TDF-FTC), while 12 participants who declined PrEP made up the control group.

Results

At enrolment the mean CD4 counts of the women of the respective group were 424 cells/ μ L (TDF), 403 cells/ μ L (TDF-FTC) and 395 cells/ μ L (controls). The highest proportion of sexually transmitted infection (50%) was recorded in the control group at enrolment and also during the study (33%). Successful conceptions in each group by the 12th month of the study duration were 60.0%, 40.0% and 16.7% in the TDF, TDF-FTC and the control groups respectively. The highest rate of loss-to-follow-up of 8/12 (66.7%) was recorded in the control group. Overall, the incidence of HIV sero-conversion adjusted for the loss-to-follow-up in the study was 9/33 (27.3%) and the highest group incidence was recorded in the control group at 33.3% and least in the TDF-FTC group at 6.7%. The relative reductions in the rates of HIV acquisition were 51% and 79% in the TDF only and TDF-FTC groups respectively.

Conclusions

In resource constraint settings, where assisted conception methods are either unacceptable, declined or un-affordable to male sero-discordant couples in heterosexual relationships, pre-exposure prophylaxis, preferably oral daily Tenofovir-Emtricitabine combination may be considered in addition to other HIV prevention strategies and timed sexual exposure, towards achieving safe reproductive health needs.

KEYWORDS: HIV, Pre-Exposure Prophylaxis, Sero-Discordant Heterosexual Partners, Reproductive Desire

INTRODUCTION

The World Health Organisation reports in 2010 indicated that about 68% of all people living with HIV in the world resided in the sub-Saharan Africa [WHO, 2011], of which 60% are women [WHO, 2008]. Also, in sub-Saharan Africa, 47% of HIV-infected women are reportedly in stable sero-discordant relationships [Eyawo et al., 2010]. According to a national probability study, in the United States, 52% of HIV-infected women reported being in a sero-discordant relationship and approximately half of HIV sero-discordant heterosexual couples desire children [Chen et al., 2001]. These needs in Africa and other low resource economies with greatest burden of HIV are recognised, but are currently not fully determined [Iliyasu et al., 2009, Oladapo et al., 2005, Hughes et al., 2012]. For these populations of patients in low-resource countries, with greatly hampered economic strength and high cost of assisted conception methods. The option left is natural conception through heterosexual relationship. This however is fraught with high risk of HIV acquisition. Beyeza-Kashesya et al. (2010) reported from Uganda that 59%, of the participants, desired to have children. The belief that their partner wanted children was a major determinant of the desire to have children, irrespective of the HIV sero-status. Among couples in which the woman was HIV-positive, young age and relatives' expectations for children were significantly associated with increased fertility desire. Oladapo et al. (2005) in South-western Nigeria reported that despite the fact that 79.6% of the respondents already had 1 or more children, 68.4% of women aged 18-45 and 53.8% of men aged 18-55 still desire children [6]. Pre-exposure prophylaxis (PrEP) in conjunction with other HIV prevention strategies provides the only veritable and possibly safe mean of achieving their reproductive desire.

PrEP still remain an emerging intervention strategies in HIV prevention programs with attempts to provide guidelines and recommendations on its application amongst both heterosexual and same sex sero-discordant couples [WHO, 2012]. At the moment drugs reported with some benefits are oral tenofovir (TDF), combination of oral tenofovir (TDF)/emtricitabine (FTC) or Tenofovir vaginal gel [WHO, 2012, Baeten et al., 2012, Okwundu et al., 2012].

This study reports our experience with PrEP amongst some sero-discordant heterosexual couples in our practice.

MATERIALS & METHODS

This is a cohort study of 42 HIV-1 sero-discordant male partners of known HIV-1 positive women and desirous of conception. The study was conducted between March 2008 and July 2010, at Ladoke Akintola University of Technology Teaching Hospital Osogbo, Nigeria. All the male Participants recruited were aware of their female partners' status, had their HIV status determined by Fourth generation Enzyme Linked Immunosorbent Assay (GENSCREEN® Ultra HIV Ag/Ab, Bio-Rad,) Kit and were HIV negative, but declined the offer of assisted conception. The HIV positive women were all on Highly Active Antiretroviral Therapy (HAART) of Zidovudine 300mg b.d, Lamivudine 150mg b.d and Nevirapine 200mg b.d combination and their baseline CD4 counts were above 350 cells/uL.

Thirty sero-discordant male partners voluntarily accepted antiretroviral therapy for use as pre-exposure prophylaxis; however 12 partners who declined both the assisted conception methods and the offer of pre-exposure prophylaxis, were enrolled as the control arm. The thirty participants, had their baseline serum creatinine and creatinine clearance determined (>60ml/minute by Cochrout-Gault formula) at enrolment into the study and thereafter commenced on oral PrEP. Enrolments were randomly by balloting, into daily tenofovir disoproxil fumarate 300 mg (TDF) or combination of daily oral tenofovir disoproxil fumarate 300 mg (TDF)/emtricitabine 200 mg (FTC). All the participants gave informed consents and received a comprehensive package of HIV-1 prevention services: HIV-1 testing with counselling before and after testing, individual and couples risk-reduction counselling, screening and treatment for sexually transmitted infections [STIs] including hepatitis B infection and free condoms with training and counselling. Also, none of the sero-discordant

male partner was uncircumcised. HIV screening with the Ag/Ab kit were repeated in the sero-discordant male partners at interval of every 3 months, as well as serum creatinine levels. Unprotected sexual exposures were limited to the periods of female partners' ovulation which was determined from presumptive ovulation period based on calculation (timed sexual exposure); otherwise, condom use was advised at other times. The hospital ethical clearance was obtained for the study. All participants were followed up monthly for a period of 12 months.

Data are presented as simple frequency, percentages, mean (standard deviation) and median (range) as appropriate.

RESULTS

A total of 42 sero-discordant partners of HIV positive women were recruited into the study. The two treatment groups (TDF and TDF-FTC) composed of 30 participants, were sequentially equally randomised, while the control group composed of 12 participants.

Table 1 showed the socio-demographic factors of the HIV 1 positive women, with their age range between 24 – 35 years and the parity median of 1. The CD4 counts at the point of enrolment ranged between 363 – 570cells/ μ L.

Among the sero-discordant male partners, the mean ages in the groups were 38.2 ± 4.1 years (TDF), 36.6 ± 3.2 years (TDF-FTC) and 39.1 ± 4.4 years (control) respectively. Majority of the male partners in the treatment groups (9/15 each) were of the secondary school level of education, in contrast to 7/12 in the control group with Primary school level of education. In the treatment groups, 12/15 (TDF) and 13/15 (TDF-FTC) were engaged in skilled occupation, while this group was 7/12 in the control group. Participants in the 3 groups were majorly Christians and Muslims (Table 2).

Table 3 showed at enrolment the mean CD4 counts of the respective group was 424 cells/ μ L (TDF), 403 cells/ μ L (TDF-FTC) and 395 cells/ μ L (controls) [F = 0.209; p = 0.812]. The highest proportion of sexually transmitted infection (50%) was recorded in the control group at enrolment and also during the study (33%).

The incidences of successful conception in each group by the 12th month of the study duration were 60.0%, 40.0% and 16.7% in the TDF, TDF-FTC and the control groups respectively. The highest rate of loss-to-follow-up of 8/12 (66.7%) was recorded in the control group.

Overall, the loss-to-follow-up adjusted incidence of HIV sero-conversion in the study was 9/33 (27.3%) and the highest group incidence was recorded in the control group at 33.3% and least in the TDF-FTC group at 6.7%. The relative reductions in the rates of HIV acquisition were 51% and 79% in the TDF only and TDF-FTC groups respectively (Table 4).

Side effects reported in the treatment groups were mainly nausea/vomiting in 5/15 (33.3%) of the TDF group and 7/15 (46.7%) of the patients in TDF-FTC group, Fatigue in 3/15 (20%) and 7/15 (46.7%) of the TDF and TDF-FTC groups respectively. On a preference scale, 11/15 (73.3%) and 6/15 (40%) in the TDF and TDF-FTC groups respectively, expressed satisfaction with their drug regimen.

DISCUSSIONS

The reproductive health needs of sero-discordant couples have in recent times become issues of concerns, especially in view of high cost of various assisted conception methods in the low-resource economies. Often times, many of these couples resort to un-informed and unsafe practices of unprotected heterosexual intercourse, leading to HIV

acquisition. The magnitude of the health burden of these populations in Nigeria and other developing economies are currently unknown.

Pre-exposure prophylaxis (PrEP) is the use of antiretrovirals in HIV-uninfected people to block the acquisition of HIV infection [Peng et al., 2012]. World Health Organisation (WHO) in its July 2012 publication has reported five large studies that had come to varying conclusions on the effectiveness and safety of PrEP in either sero-discordant same sex or heterosexual couples. However, the summation of systematic review of evidence by WHO concluded that in countries where HIV transmission occurs among sero-discordant couples, where discordant couples can be identified and where additional HIV prevention choices for them are needed, daily oral PrEP (specifically tenofovir or the combination of tenofovir and emtricitabine) may be considered as a possible additional intervention for the uninfected partner.

In this cohort (observational) study, we report on 42 sero-discordant male partners in heterosexual relationship with HIV-1 positive female partners, who are desirous of conception, but declined all offers of assisted conception methods. Majority of the sero-discordant male partners in the 3 groups were Christians and were in skilled occupations. However, there was a preponderance (7/12) of primary/elementary education levels among the control group. This might have influenced the decision making abilities in this group, who despite health education and counselling, they declined both the offers of assisted conception methods and PrEP. Peng et al. (2012) had reported that education level influenced willingness to accept PrEP with 32.8% of Chinese female sex workers with elementary levels of education unwilling to use PrEP.

The immunological statuses of the HIV-1 positive female partners were comparable across the groups and all were highly motivated and regular on HAART. However, the incidences of STIs at both enrolment and during the study were proportionately highest in the control group's female partners. Hayes et al reviewing evidences from observational and biologic data had concluded that evidence strongly supports the concept that STI treatment prevents HIV infection [Hayes et al., 2010], though doubts have been raised about link between STI and HIV risk, because intervention studies are not conclusive, possibly because mechanisms of action and the design and implementation of interventions are not clearly understood [Ward and Ronn, 2010]. In this study, identified STIs were promptly treated in both partners to minimize the risk of HIV acquisition.

The findings in our study suggested that once-daily oral TDF and TDF-FTC were associated with risk reductions of 51% and 79% respectively against HIV-1 infection acquisition in sero-discordant male partners, when combined with other HIV-1 prevention services and timed sexual exposure. These findings are similar to those reported by Baeten et al., though the risk reduction in our study with oral TDF was 51%, which is lower than the 67% reported by Baeten et al. [Baeten et al., 2012]. Also Thigpen et al. (2012) had reported an overall 63% risk reduction in heterosexual men and women in Botswana. However, another study reported that with higher levels of adherence, as suggested by TDF levels in plasma, the effectiveness of oral TDF was 86% and that of the TDF/FTC combination was 90% [Donnel et al., 2012].

However, while effectiveness of PrEP seems clearer amongst sero-discordant male partners in this and other studies, reports are conflicting amongst women. The trial of daily oral TDF/FTC in African women at higher risk of HIV in Kenya, South Africa and the United Republic of Tanzania was terminated early, when equal numbers of infections were seen in the PrEP and placebo arms at interim analysis. The likely cause of apparent futility of this study had been attributed to poor adherence, with resultant low drug concentrations in study participants [Van Damme et al., 2012].

The desire for natural conception in these couples necessitated this study and overall conception rate over the 12 months study period was 40.5% (17/42). The incidence of group conception was highest (60%) in the TDF group and least

(16.7%) in the control group. However, with very high loss to follow-up (66.7%) in the control conception in this group might be under-reported. In this study, our great concerns were problems of adherence, loss to follow-up and possible drug resistance. To mitigate the first two concerns, monthly follow-up meetings were scheduled for each couple to address all emerging issues and re-emphasize risk-reduction counselling, as well as evaluate and support PrEp adherence. Evaluation for drug resistance is presently not available in our institution.

HIV acquisition incidences were 16.3%, 6.7% and 33.3% respectively in the TDF, TDF-FTC and control groups. This translated to HIV acquisition risk reduction of 51% and 79% for both the TDF and TDF-FTC groups in this study respectively. Side effects recorded in the treatment groups were mainly nausea/vomiting in 33.3% of the TDF group and 46.7% of the patients in TDF-FTC group and Fatigue in 20% and 46.7% of the TDF and TDF-FTC groups respectively. On preference scale, 11/15 (73.3%) and 6/15 (40%) in the TDF and TDF-FTC groups respectively, expressed satisfaction with their drug regimen. While TDF has been reported to cause small, but insignificant reduction in the glomerular filtration rates in a population of HIV-1 positive patients [Cooper et al., 2010]. This observation could not be ascertained in our study, as none of the patients had evidence of elevated serum creatinine throughout the study. However, the small size and the limited duration of our study preclude a definite statement in this regard.

The recorded side effects and patients' likely preference/tolerability of drug burden might be some factors to consider in drug adherence issues and should be addressed at every session of counselling, to elicit the maximum understanding and cooperation of the patients. In our study, the highest incidence was recorded in the first 6 weeks of commencing the PrEp and abated thereafter.

While this our study is observational in nature, the limitations inherent are the small population of participants, high incidence of loss-to-follow-up and infrastructural constraints resulting in inability to determine viral load in the HIV positive female partners, inability to assess for drugs serum levels in the male sero-discordant partners to monitor adherence and Viral sensitivity test to determine possible drug resistance.

CONCLUSIONS

In resource constraint settings, where assisted conception methods are either unacceptable, declined or unaffordable to male sero-discordant couples in heterosexual relationships, pre-exposure prophylaxis, preferably oral daily Tenofovir-Emtricitabine combination may be considered in addition to other HIV prevention strategies and timed sexual exposure, towards achieving safe reproductive health needs.

ACKNOWLEDGEMENTS

We are grateful to all our patients who consented to participate in this study and all our resident Doctors and other personnel that assisted in the conduct of the study.

DISCLOSURE

The authors report no conflicts of interest in this work.

Table 1: Socio-Demographic Factors of HIV 1 Positive Women

Factors	Characteristics
AGE, median (range)	28 (24 – 35)
PARITY, median (range)	1 (0 – 2)
CD4 count at enrolment [Cells/ μ L], median (range)	405 (363 – 570)

Table 2: Characteristics of Sero-Discordant Male Partners

Characteristics	TDF Group n = 15	TDF-FTC Group n = 15	Controls n = 12
AGE , mean (SD)	38.2 (4.1)	36.6 (3.2)	39.1 (4.4)
EDUCATIONAL STATUS			
None	-	-	2
Primary	4	6	7
Secondary	9	9	3
Tertiary	2	-	-
OCCUPATION			
Unemployed	-	-	-
Unskilled	2	2	5
Skilled	12	13	7
Professional	1	-	-
RELIGION			
Traditional	1	-	2
Christianity	7	9	5
Islam	7	6	5

Table 3: CD4 Count Status at Enrollment & Incidence of Sexually Transmitted Infections in the HIV Positive Women

Factors	TDF n = 15	TDF-FTC n = 15	Control n = 12
CD4 COUNT AT ENROLLMENT [Cells/ μ L], mean (SD)	424 (135)	403 (121)	395 (105)
STI (At enrolment), n (%)	1 (6.7)	3 (20.0)	6 (50.0)
STI (During study), n (%)	-	1 (6.7)	4 (33.3)

STI = Sexually Transmitted Infection

Table 4: Incidence of Conception, Loss to Follow-up in the Study Groups and HIV Infection in Male Partners

Factors	TDF n = 15	TDF-FTC n = 15	Control n = 12
CONCEPTION			
Conception at 6 months	3	2	-
Conception at 7 - 12 months	6	4	2
No of conception by 12 month, n (%)	9 (60)	6 (40)	2 (16.7)
LOSS TO FOLLOW-UP			
Loss to follow-up at 6/12	-	-	3
Loss to follow-up at 12/12	-	1	5
Total Number of Loss to Follow-up, n (%)	-	1 (6.7)	8 (66.7)
No of Participants who completed the study, n (%)	15 (100)	14 (93.3)	4 (33.3)
INCIDENCE OF HIV SEROCONVERSION IN PARTNERS	2 (16.3)	1 (6.7)	4 (33.3)

REFERENCES

1. Baeten JM et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *New England Journal of Medicine*. Published online ahead of press 11 July 2012, <http://www.nejm.org/doi/full/10.1056/NEJMoal108524>.
2. Beyeza-Kashesya J, Ekstrom AM, Kaharuzza F, Mirembe F, Neema S, Kulane A. My partner wants a child: a cross-sectional study of the determinants of the desire for children among mutually disclosed sero-discordant

- couples receiving care in Uganda. *BMC Public Health*. 2010 May 13; 10:247. <http://dx.doi.org/10.1186/1471-2458-10-247>.
3. Chen J. L, Phillips K. A, Kanouse D. E, Collins R. L, and Miu A. Fertility desires and intentions of HIV-positive men and women. *Family Planning Perspectives*, vol. 33, no. 4, pp. 144–152, 2001.
<http://dx.doi.org/10.2307/2673717>. PMID:11496931
 4. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. *Clin Infect Dis* 2010; 51:496-505.
<http://dx.doi.org/10.1086/655681>. PMID:20673002
 5. Donnell D et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 2012. Abstract 30.
 6. Eyawo O, de Walque D, Ford N, Gakii G, Lester R. T, and Mills E. J. HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. *The Lancet Infectious Diseases*, vol. 10, no. 11, pp. 770–777, 2010. [http://dx.doi.org/10.1016/S1473-3099\(10\)70189-4](http://dx.doi.org/10.1016/S1473-3099(10)70189-4).
 7. Hayes Richard, Watson-Jones Deborah, Celum Connie, van de Wijgerd Janneke, Wasserheit Judith. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? *AIDS* 2010, 24 (suppl 4):S15–S26. <http://dx.doi.org/10.1097/01.aids.0000390704.35642.47>. PMID: 21042049
 8. Hughes J. P, Baeten J. M, Lingappa J. R, et al. Determinants of per-coital act HIV-1 infectivity among African HIV-1 sero-discordant couples. *Journal of Infectious Disease*, vol. 205, no. 3, pp. 358–365, 2012.
<http://dx.doi.org/10.1093/infdis/jir747>. PMID:22241800 PMCid:3256946
 9. Iliyasu Zubairu, Abubakar Isa S, Kabir Mohammed, Babashani Musa, Shuaib Faisal and Aliyu Muktar H. Correlates of Fertility Intentions among HIV/AIDS Patients in Northern Nigeria. *African Journal of Reproductive Health*. Vol. 13, No. 3 (September 2009), pp. 71-84.
 10. Okwundu CI, Uthman OA, Okoromah CAN. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals (Review). *Cochrane Library* 2012, Issue 12.
www.thecochranelibrary.com/details/file/.../CD007189.html. [Accessed: 27 December 2012]
 11. Oladapo Olufemi T, Daniel Olusoji J, Odusoga Okanlawon L, Ayoola-Sotubo Oluwafayokemi. Fertility Desires and Intentions of HIV-Positive Patients at a Suburban Specialist Center. *Journal of the National Medical Association* Vol. 97, NO. 12, December 2005: 1672 – 1681.
 12. Peng B, Yang X, Zhang Y et. al. Willingness to use pre-exposure prophylaxis for HIV prevention among female sex workers: a cross-sectional study in China. *HIV/AIDS - Research and Palliative Care* 2012;4 149–158
 13. Thigpen MC et al. Antiretroviral pre-exposure prophylaxis for heterosexual HIV transmission in Botswana. *New England Journal of Medicine*. Published online ahead of press 11 July 2012.
<http://www.nejm.org/doi/full/10.1056/NEJMoa1110711>

14. Van Damme L et al. Pre-exposure prophylaxis for HIV infection among African women. *New England Journal of Medicine*. Published online ahead of press 11 July 2012. <http://www.nejm.org/doi/full/10.1056/NEJMoa1202614>.
15. Ward Helen and Rönn Minttu. The contribution of STIs to the sexual transmission of HIV. *Curr Opin HIV AIDS*. 2010 July; 5(4): 305–310. <http://dx.doi.org/10.1097/COH.0b013e32833a8844>. PMID: 20543605. PMCID: 2923028
16. WHO (2008). Gender inequalities and HIV. http://www.who.int/gender/hiv_aids/en/. [Accessed: 10 April 2013].
17. WHO (2011). Global HIV/AIDS response, Epidemic update and health sector progress towards Universal Access. Progress Report 2011. http://www.who.int/hiv/pub/progress_report2011/en/. [Accessed: 27 February 2013]
18. WHO (July 2012). Guidance on oral pre-exposure prophylaxis (PrEP) for sero-discordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. http://www.who.int/hiv/pub/guidance_prep/en/. [Accessed: 27 February 2013]